ArticleBMJ open2026
Necessity and safety of primary closure of the patent processus vaginalis in laparoscopic orchiopexy: protocol for systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA patent processus vaginalis (PPV) is frequently observed during laparoscopic orchiopexy in infants with cryptorchidism. Nevertheless, the decision to primarily close the PPV following laparoscopic orchiopexy remains a subject of debate. This protocol therefore outlines the scope and methodology for a systematic review and meta-analysis that will synthesise the available evidence to evaluate the clinical outcomes associated with primary closure of the PPV after laparoscopic orchiopexy. METHODS AND ANALYSIS: A systematic electronic literature search will be conducted across PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov to identify eligible studies published before 31 May 2026. The methodological quality of the included studies will be assessed using the Cochrane Risk of Bias V.2 tool for randomised trials and the Risk of Bias in Non-randomized Studies of Interventions tool for non-randomised studies. The primary outcomes will include postoperative inguinal hernia, testicular atrophy and testicular ascent. Secondary outcomes will comprise operative time, estimated blood loss, length of postoperative hospital stay and overall 30-day postoperative complications. The robustness of the findings will be evaluated through subgroup analyses and sensitivity analyses. All statistical analyses will be performed using Stata 19.0 and RevMan Web, with statistical significance defined as a two-sided p < 0.05. The certainty of the evidence will be evaluated following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. ETHICS AND DISSEMINATION: Ethical approval for this study based solely on aggregated and anonymised data is not required. Findings will be disseminated through peer-reviewed journals, conferences and interactive dialogues in this research area. PROSPERO REGISTRATION NUMBER: CRD420261289759.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.